180 related articles for article (PubMed ID: 31765737)
61. Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).
Lei X; Hu X; Lu Q; Fu W; Sun W; Ma Q; Huang D; Xu Q
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36799184
[TBL] [Abstract][Full Text] [Related]
62. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
63. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
64. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
65. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
66. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
67. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
68. Accuracy of mutational signature software on correlated signatures.
Wu Y; Chua EHZ; Ng AWT; Boot A; Rozen SG
Sci Rep; 2022 Jan; 12(1):390. PubMed ID: 35013428
[TBL] [Abstract][Full Text] [Related]
69. Gaining insights into relevance across cancers based on mutation features of TP53 gene.
Mei Y; Liang D; Wang T; Yu D
Biochem Biophys Rep; 2021 Dec; 28():101165. PubMed ID: 34786492
[TBL] [Abstract][Full Text] [Related]
70. Exploration of the role of serum ghrelin in the diagnosis and treatment of digestive tract malignancies.
Zhu C; Liu Y; Kang W; Zhang Z; Zeng Z; Liu D
J Int Med Res; 2020 May; 48(5):300060520920441. PubMed ID: 32366148
[TBL] [Abstract][Full Text] [Related]
71. Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy.
Zhang Y; Sun J; Song Y; Gao P; Wang X; Chen M; Li Y; Wu Z
Crit Rev Oncol Hematol; 2022 Mar; 171():103622. PubMed ID: 35124200
[TBL] [Abstract][Full Text] [Related]
72. The impact of site-specific digital histology signatures on deep learning model accuracy and bias.
Howard FM; Dolezal J; Kochanny S; Schulte J; Chen H; Heij L; Huo D; Nanda R; Olopade OI; Kather JN; Cipriani N; Grossman RL; Pearson AT
Nat Commun; 2021 Jul; 12(1):4423. PubMed ID: 34285218
[TBL] [Abstract][Full Text] [Related]
73. Improvement in prediction of prostate cancer prognosis with somatic mutational signatures.
Zhang S; Xu Y; Hui X; Yang F; Hu Y; Shao J; Liang H; Wang Y
J Cancer; 2017; 8(16):3261-3267. PubMed ID: 29158798
[TBL] [Abstract][Full Text] [Related]
74. Digestive tract neoplasms in young individuals: Demographics, staging and risk factors.
Tasneem AA; Luck NH
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1319. PubMed ID: 33295088
[TBL] [Abstract][Full Text] [Related]
75. Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine.
Molnar A; Monroe H; Basri Aydin H; Arslan ME; Lightle A; Lee H; El Jabbour T
Curr Oncol; 2023 Feb; 30(2):2388-2404. PubMed ID: 36826143
[TBL] [Abstract][Full Text] [Related]
76. CoMI: consensus mutual information for tissue-specific gene signatures.
Huang SH; Lo YS; Luo YC; Chuang YH; Lee JY; Yang JM
BMC Bioinformatics; 2022 Apr; 22(Suppl 10):624. PubMed ID: 35439942
[TBL] [Abstract][Full Text] [Related]
77. Predicting clinical outcomes using cancer progression associated signatures.
Mamrot J; Hall NE; Lindley RA
Oncotarget; 2021 Apr; 12(8):845-858. PubMed ID: 33889305
[TBL] [Abstract][Full Text] [Related]
78. Intratumoral microorganisms in tumors of the digestive system.
Xuan M; Gu X; Liu Y; Yang L; Li Y; Huang D; Li J; Xue C
Cell Commun Signal; 2024 Jan; 22(1):69. PubMed ID: 38273292
[TBL] [Abstract][Full Text] [Related]
79. Deep Learning-Based Pan-Cancer Classification Model Reveals Tissue-of-Origin Specific Gene Expression Signatures.
Divate M; Tyagi A; Richard DJ; Prasad PA; Gowda H; Nagaraj SH
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267493
[TBL] [Abstract][Full Text] [Related]
80. Gastrointestinal oncology--what you need to know.
Smyth E; Cunningham D
Clin Med (Lond); 2012 Dec; 12(6):575-9. PubMed ID: 23342414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
